Cite
HARVARD Citation
Bendell, J. et al. (n.d.). 388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors. Journal for immunotherapy of cancer. p. A413. [Online].